abstract: UNASSIGNED: 9736 Background: Evaluation of @entity1486 ( @entity1486 ) is the current screening method for early detection of @entity263 . @entity1486 is more prostate specific than @entity5 specific, and elevated @entity1486 can also be found in benign conditions of the prostate. Thus, in spite of the overall success of @entity1486 screening, there is a continued need for more sensitive and specific methods for early detection of @entity263 . METHODS: We have developed an antibody-based approach to biomarker discovery in @entity5 , focusing on differential protein expression, using: i) a large collection of high affinity polyclonal antibodies raised against individual @entity1 proteins and their isoforms; ii) a proprietary multiplex protein array immunoassay, namely the matrix protein array technology (MPAT), coupled to a readout and data analysis system, and iii) clinical samples (tissue and serum) from normal, @entity1067 ( @entity1067 ), early and @entity263 @entity1 . Protein extracts from specimens were printed onto a membrane, then allowed to interact with 20,000 individual antibodies from our collection. Antibody-sample reaction was detected by chemiluminescence, and quantified by computer analysis of a CCD-acquired image, followed by statistical analysis. RESULTS: In the screening of tissue specimens we have identified three distinct panels of antibodies, specific for @entity5 , @entity263 , respectively. In addition, screening of 150 serum samples revealed antibody panels discriminating @entity5 . We have further characterized these biomarkers by western blot analysis. CONCLUSIONS: These biomarkers offer potential applications in the early diagnosis of @entity263 , and discrimination from benign conditions of the prostate. [Table: see text].

title: Candidate secreted biomarkers for XXXX detection.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer', 'BPH and prostate tumor', 'advanced prostate cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'early versus late stage prostate cancer']

entities_list: @entity1067 :: ('MESH:D011470', 'Disease') :: ['benign prostate hyperplasia', 'BPH']

entities_list: @entity1486 :: ('354', 'Gene') :: ['PSA', 'prostate specific antigen']

answer: @entity263 :: (MESH:D011471,Disease) :: ['early prostate cancer']


abstract: Three cases of @entity438 associated with @entity884 are reported. All of the @entity1 were successfully treated by various combinations of cardiac surgery, neurosurgery and chemotherapy with antibiotics. Case 1: A 39-year-old female was admitted with the complaint of sudden onset of severe @entity10 following persistent @entity221 of @entity21628 's duration. CT scan revealed a left frontal old @entity1410 and angiography detected an @entity439 located in the frontal ascending branch of the left middle cerebral artery. After 2 weeks' antibiotic therapy, the second angiography showed the @entity439 to be decreased in size. The third angiography, performed 2 weeks after @entity299 for @entity884 , demonstrated complete resolution of the @entity439 . Case 2: A 19-year-old male entered hospital with high @entity221 and chills. In addition to @entity884 , CT scan and angiography revealed an @entity439 arising from the distal portion of the left posterior cerebral artery. The @entity1 was treated with high dose antibiotics and then his general condition improved. However, angiography examined 4 weeks after the initial study demonstrated the @entity439 to be apparently enlarged. Therefore, the @entity439 was excised before cardiac surgery. Repeated angiography after valve replacement showed no further @entity439 . Case 3: A 30-year-old female was admitted on the diagnosis of @entity884 and @entity693 . CT scan showed abnormal density areas in the right frontal lobe and the left temporal lobe.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Bacterial XXXX associated with infectious endocarditis--report of 3 cases].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity438 :: ('MESH:D002532', 'Disease') :: ['bacterial intracranial aneurysms']

entities_list: @entity21628 :: ('MESH:C536711', 'Disease') :: ['several month']

entities_list: @entity693 :: ('MESH:D008581', 'Disease') :: ['meningitis']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysm']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac valve replacement']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

entities_list: @entity884 :: ('MESH:D004696', 'Disease') :: ['infective endocarditis']

answer: @entity438 :: (MESH:D002532,Disease) :: ['intracranial aneurysms']


abstract: @entity28223 modulates a variety of cell functions such as adhesion, spreading, and migration. Using a fusion protein consisting of the extracellular region of Src homology 2 domain bearing protein @entity669 phosphatase substrate-1 ( @entity28224 ) and the Fc portion of @entity1 Ig ( @entity28224 -Ig) we investigated the effects of @entity28224 as a ligand for @entity28223 on B lymphocytes. Although @entity28224 -Ig binding to @entity1 B cell lines was solely mediated via @entity28223 , their binding capacity for soluble and immobilized @entity28224 -Ig varied among cell lines irrespective of the similar expression levels of @entity28223 , suggesting that distinctive affinity/avidity states exist during B cell maturation. @entity1 cell line and tonsilar B lymphocytes adhered to immobilized @entity28224 -Ig and showed polarization-like morphology. These effects of @entity28224 -Ig were blocked by anti- @entity28223 mAbs (B6H12 and SE5A5). Wortmannin, a @entity4357 -3 kinase inhibitor, but not pertussis toxin significantly inhibited the polarization induced by the immobilized @entity28224 -Ig. Thus, @entity28224 acts as an adhesive substrate via @entity28223 in @entity1 B lymphocyte. Immunohistochemical analyses indicated that @entity28224 is expressed on high endothelial venule as well as macrophages in @entity1 tonsils. HUVECs also express @entity28224 in the absence of any stimuli, and the adhesion of tonsilar B lymphocytes to nonactivated HUVECs was significantly inhibited by SE5A5, indicating that @entity28224 / @entity28223 interaction is involved in the adhesion. Our findings suggest that @entity28224 / @entity28223 interaction may contribute to the recruitment of B lymphocytes via endothelial cells under steady state conditions.

title: Interaction between Src homology 2 domain bearing protein @entity669 phosphatase substrate-1 and XXXX mediates the adhesion of @entity1 B lymphocytes to nonactivated endothelial cells.

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

entities_list: @entity4357 :: ('MESH:D010716', 'Chemical') :: ['phosphatidylinositol']

answer: @entity28223 :: (961,Gene) :: ['CD47']


abstract: PURPOSE: The purpose of this study was to evaluate the effect of the Rel homology domain (RHD) of the transcription factor, nuclear factor kappa B ( @entity1991 ), on proinflammatory gene expression in bone marrow-derived dendritic cells (BMDCs). EXPERIMENTAL DESIGN: We used an adenovirus vector encoding only the RHD of the @entity1991 ( @entity1992 family member) cDNA (AdRHD) to transduce @entity19 BMDCs ex vivo. Endpoints measured included BMDC expression of activation markers, cytokine secretion, peptide antigen presentation, and the ability of these transduced cells to induce antitumor immunity in vivo. RESULTS: AdRHD-transduced BMDCs secreted higher levels of the cytokines @entity635 , @entity777 , and IL-12 ( @entity12782 ) compared with sham-transduced BMDCs or those transduced with an empty vector. AdRHD induced heightened surface expression of the activation markers @entity14636 , B7.1, B7.2, and MHC class II on BMDCs, and these cells were able to present a peptide antigen to a T-lymphocyte hybridoma more efficiently than controls in vitro. Growth of syngeneic, established @entity5 (CT26 and B16.F10) was inhibited, and survival was prolonged in the @entity19 that received intratumoral AdRHD-modified BMDCs compared with controls. Splenocytes from CT26 @entity5 -bearing animals that received intratumoral AdRHD-modified BMDCs were able to lyse CT26 target cells more efficiently than controls. Similar experiments using host @entity19 harboring targeted mutations in @entity1961 and CD8, as well as BMDCs from @entity19 lacking MHC class I, MHC class II, or IL-12 revealed that this @entity5 immunity was dependent on the presence of @entity1961 + and CD8+ cells in the @entity5 -bearing host, as well as MHC class I, MHC class II, and IL-12 expression by the administered BMDCs. Furthermore, induction of IL-12 ( @entity12782 ) expression by AdRHD was completely abrogated in BMDCs lacking the @entity16181 @entity1991 family member. CONCLUSIONS: We made the following conclusions: (a) gene transfer-mediated overexpression of the RHD of @entity1991 activates BMDCs; (b) AdRHD-transduced BMDCs induce antitumor immunity when administered intratumorally, an effect mediated by both the @entity1961 + T cell/MHC class II and the CD8+ T cell/MHC class I pathways, as well as IL-12; and (c) IL-12 ( @entity12782 ) up-regulation by the RHD transgene in BMDCs is dependent on the presence of the @entity16181 @entity1991 family member.

title: Adenovirus vector-mediated overexpression of a truncated form of the @entity1992 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting @entity19 XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumors']


abstract: A 54-year-old @entity1 had emergency laparoscopic chelecystectomy for acute @entity2679 . General inflammatory change (CRP 26.6 mg x dl(-1), WBC 26,800) was noted preoperatively. Anesthesia was induced with @entity1875 and @entity1937 and maintained with @entity2614 in @entity26 and @entity1937 . Operation was performed uneventfully within 128 min. At the end of the surgery, 0.1 mg of @entity3575 was administrated. After confirming adequate respiration and oxygenation, endotracheal tube was removed. At that period, @entity101 ( @entity13519 220 mmHg) and @entity591 (HR 122 beats x min(-1)) developed. Soon thereafter, he became @entity2146 and complained of @entity1353 with desaturation (Spo2 < 70%). After reintubation, massive pinkish babbly secretion flowed out from the endotracheal tube. Chest X-ray revealed diffuse bilateral infiltration of the lungs without @entity1283 . He was transferred to the intensive care unit for mechanical ventilation. His condition improved progressively and was extubated on the POD 6. The cause of @entity3126 is thought to be profound centralization of circulating volume associated with @entity2922 -induced vasoconstriction due to rapid disappearance of @entity1937 effect. Adequate analgesia is necessary during @entity1937 -based anesthesia especially in @entity1 suffering from general inflammatory changes.

title: [Case of XXXX due to excessive @entity101 following extubation].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'man']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity3126 :: ('MESH:D011654', 'Disease') :: ['pulmonary edema']

entities_list: @entity1283 :: ('MESH:D006332', 'Disease') :: ['cardiomegaly']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['tachycardia']

entities_list: @entity2679 :: ('MESH:D002764', 'Disease') :: ['cholecystitis']

entities_list: @entity1875 :: ('MESH:D015742', 'Chemical') :: ['propofol']

entities_list: @entity2614 :: ('MESH:C009250', 'Chemical') :: ['sevoflurane']

entities_list: @entity2922 :: ('CHEBI:33567', 'Chemical') :: ['catecholamine']

entities_list: @entity3575 :: ('MESH:D005283', 'Chemical') :: ['fentanyl']

entities_list: @entity1937 :: ('MESH:C071741', 'Chemical') :: ['remifentanil']

answer: @entity3126 :: (MESH:D011654,Disease) :: ['pulmonary edema']


abstract: 19S IgM rheumatoid factors (RF) are polyclonal autoantibodies that may play an important pathogenic role in sustaining inflammatory @entity603 in @entity309 ( @entity309 ). RF in @entity309 have reactivity for as-yet-uncharacterized antigenic determinants in IgG Fc. We hypothesized that qualitative differences might exist between some of these RF molecules, and that differences such as reactivity and affinity might characterize more pathogenic RF molecules. Previous observations in our laboratory indicate that RF produced by rheumatoid synovial cells (RSC) have greater reactivity with human IgG and @entity3172 subclass, in contrast to serum RF, which has greater reactivity with rabbit IgG and human IgG1. These observations were made using a complement-dependent RF plaque-forming cell assay. The purpose of this study was to validate and extend those observations. Therefore, we examined the reactivity of RSC and serum RF with @entity1 and rabbit IgG and the reactivity and avidity of RSC-RF for IgG1 and @entity3172 molecules and @entity1334 , F(ab')2, and pFc' fragments thereof in a solid-phase enzyme immunoassay. In particular, we found: RSC-RF had at least twice as much reactivity with human IgG as with rabbit IgG; serum RF had approximately equal reactivity with @entity1 and rabbit IgG; RSC-RF had greater reactivity and avidity for @entity3172 and @entity3172 pFc' than for IgG1; and RSC-RF was nonreactive with @entity1334 or F(ab')2 from either IgG1 or @entity3172 . These results suggest that the major antigenic determinant for RSC-RF resides in the CH3 domain of the @entity3172 molecule. Precise characterization of this epitope may provide further insight into the etiology and pathogenesis of @entity309 .

title: Differential reactivity of rheumatoid synovial cells and serum rheumatoid factors to XXXX immunoglobulin G subclasses 1 and 3 and their CH3 domains in @entity309 .

entities_list: @entity603 :: ('MESH:D013585', 'Disease') :: ['synovitis']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: OBJECTIVE: The authors present their 35-year experience with intra-arterial chemotherapeutic regional perfusion of 1139 @entity1 with @entity320 , using an extracorporeal oxygenated circuit and heart-lung apparatus. SUMMARY BACKGROUND DATA: Intra-arterial chemotherapy produces improved responses in many @entity5 . By isolating and sustaining the area with extracorporeal oxygenated circulation, high doses can be delivered to the @entity5 area, limited only by local @entity137 . Drug levels up to 10 times those achieved by systemic administration are obtained. METHODS: Techniques for hyperthermic perfusion were developed for limbs, pelvis, head, neck, and skin of the breast. Melphalan (Burroughs Wellcome, Research Triangle Park, NC) was used in 753 @entity1 . Combinations with melphalan or other drugs were used in remaining cases at temperature of 38 to 40 C for 30 to 60 minutes. RESULTS: Chemotherapy perfusion followed by @entity5 excision or node dissection, was performed where indicated. The cumulative 10-year survival for @entity1 with localized @entity320 was 70%. For @entity1 with local recurrences or satellites within 3 cm, survival was 61%. For those with regionally confined intransit @entity5 , survival was 30%; for those with regional node involvement, 38%; for those with intransit and nodal @entity3 , 16%; for those with distant @entity3 and perfusion--mainly to save functional limbs--survival was 7%. Multiple perfusions were performed in 158 @entity1 with recurrent disease on 366 occasions. @entity1 with indolent regionally confined @entity320 were benefited by prolongation of useful life. CONCLUSIONS: Safe perfusion techniques are available for most anatomic regions. Increased chemotherapeutic doses are delivered to isolated areas limited only by local @entity137 . Adjunct perfusion in poor prognosis stage I cases is useful in reducing local recurrence, and intransit or lymph node @entity3 . Regional perfusion reduces the need for major amputation. Multiple perfusion can be useful in treating recurrent chronic @entity320 .

title: Regional chemotherapy for XXXX . A 35-year experience.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'melanomas']

answer: @entity320 :: (MESH:D008545,Disease) :: ['melanoma']


abstract: Out of every 17-18 individuals in the US, one develops @entity14 ( @entity14 ) in their lifetime. Of individuals diagnosed with @entity14 , > 50% present or develop @entity3 , which, if untreated, is associated with 6-9 months median survival. Although surgical resection is the primary treatment modality for @entity14 , chemotherapy is the mainstay of treatment for metastatic or unresectable disease. For nearly three decades, @entity1487 ( @entity1487 ) has been the chemotherapy of choice for treatment of @entity14 . However, the response rates to single @entity1487 therapy have been suboptimal with an objective @entity5 response of 10-20%. Attempts have been made to improve the efficacy of @entity1487 by either schedule alteration (protracted infusion versus intravenous push) or biochemical modulation with @entity4181 (LV). Continuous infusion induced more @entity5 regression and prolonged the time-to-disease progression with some significant impact on survival (11.3 versus 12.1 months; p < 0.04). @entity1487 /LV resulted in a significant increase in overall response rates and in the prolongation of disease-free survival in the adjuvant setting, although severe @entity137 represent a major clinical problem. The last 10 years have seen the addition of several new agents such as @entity2600 , @entity901 , raltitrexed, bevacizumab and cetuximab. The prognosis has significantly improved with the addition of these agents, with median survivals now > 20 months. This review paper focuses on @entity2600 , @entity901 and raltitrexed when used alone and in combination.

title: @entity2600 , @entity901 and raltitrexed for the treatment of advanced XXXX .

entities_list: @entity4181 :: ('MESH:D002955', 'Chemical') :: ['leucovorin']

entities_list: @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities']

entities_list: @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['CRC', 'colorectal cancer']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']


abstract: We report a 78-year-old @entity1 who had episodes of @entity159 ( @entity159 ) with @entity1296 . At 75 years of age, she had first @entity410 , but was not well examined. At 78 years of age, she had brief myoclonic jerks of her arms, soon after awakening, in May. She suffered from strong @entity1296 and was admitted in our hospital at the end of June. The symptoms regressed with bed rest in few days and she was discharged. However, she was admitted again with @entity1296 in the middle of July. There were no myoclonic jerks of her arms or legs and she could converse and interact normally, but was slightly disoriented (JCS: 2). Blood test, Cerebrospinal fluid analyses and brain MRI were normal. An EEG showed frequent intermittent generalized multiple spikes and slow wave complexes and a 3-4 Hz generalized spike and slow wave complexes every 2-4 seconds during whole 20 minutes record. Intravenous injection of 5 mg @entity3175 terminated status immediately. Thereafter, she was treated with @entity1092 (400 mg/day). Her symptoms improved, and interictal @entity302 discharges extremely decreased. Late-onset @entity159 of @entity6191 is rare. We discussed this case as an important case for diagnosis of @entity159 with subtle symptom of @entity1296 .

title: [A late-onset case of @entity159 of XXXX ].

entities_list: @entity3175 :: ('MESH:D003975', 'Chemical') :: ['diazepam']

entities_list: @entity1092 :: ('MESH:D014635', 'Chemical') :: ['sodium valproate']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epileptic']

entities_list: @entity6191 :: ('MESH:D004829', 'Disease') :: ['generalized epilepsy']

entities_list: @entity1296 :: ('MESH:D004244', 'Disease') :: ['dizziness']

entities_list: @entity159 :: ('MESH:D013226', 'Disease') :: ['nonconvulsive status epilepticus', 'NCSE']

answer: @entity6191 :: (MESH:D004829,Disease) :: ['generalized epilepsy']


abstract: OBJECTIVE: To estimate the incidence of @entity3 and @entity55 , distribution of pneumococcal serotypes, and antibiotic susceptibility in @entity1 aged 28 days to <60 months. DESIGN: Hospital-based surveillance. SETTING: South Bangalore, India. @entity1 : 9950 @entity1 aged 28 days to <60 months with clinical suspicion of @entity3 or @entity55 . RESULTS: The estimated at-risk population included 224,966 @entity1 <5 years of age. Forty cases of @entity3 were identified. Estimated @entity3 incidence was 17.8/100,000 with incidence being highest among @entity1 aged 6 months to <12 months (49.9/100,000). @entity922 was the most frequent diagnosis (12.5/100,000). Pneumococcal serotypes included: 6A (n=6, 16.7%); 14 (n=5, 13.9%); 5 (n=4, 11.1%); 6B (n=4, 11.1%); 1, 18C, and @entity5686 (n=3 each, 8.3%); 9V (n=2, 5.6%); and 3, 4, 10C, 18A, 18F, and 19F (n=1 each, 2.8%). Serotypes 6A, 14, 6B, 1, 18C, @entity5686 , 9V, 4, 10C, and 18A showed antibiotic resistance. Clinical @entity55 incidence was 2109/100,000, with incidence being highest among @entity1 aged 28 days to <6 months (5033/100,000). Chest radiograph-confirmed @entity55 incidence was 1114/100,000, with incidence being highest among @entity1 aged 28 days to <6 months (2413/100,000). CONCLUSIONS: Invasive @entity66 and @entity55 were found to be common causes of morbidity in young @entity1 living in South Bangalore, India.

title: Hospital-based Surveillance of XXXX and @entity55 in South Bangalore, India.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'PARTICIPANTS']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['pneumococcal disease']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['invasive pneumococcal disease']

entities_list: @entity922 :: ('MESH:D013568', 'Disease') :: ['Clinical pneumonia syndrome']

answer: @entity3 :: (MESH:D009362,Disease) :: ['Invasive Pneumococcal Disease']


abstract: INTRODUCTION: Assessment of @entity1082 ) prevalence and genotype distribution is important for monitoring the impact of prophylactic HPV vaccination. This study aimed to demonstrate the HPV genotypes predominating in pre-malignant and @entity5 in Northern Ireland (NI) before the vaccination campaign has effect. METHODS: Formalin fixed paraffin embedded tissue blocks from 2,303 @entity1 aged 16-93 years throughout NI were collated between April 2011 and February 2013. HPV DNA was amplified by PCR and HPV genotyping undertaken using the Roche   linear array detection kit. RESULTS: In total, 1,241 out of 1,830 eligible samples (68.0%) tested positive for HPV, with the majority of these [1,181/1,830 (64.5%)] having high-risk (HR) @entity1083 ; 37.4% were positive for @entity1799 (n   =   684) and 5.1% for HPV-18 (n   =   93). HPV type-specific prevalence was 48.1%, 65.9%, 81.3%, 92.2% and 64.3% among @entity3146 ( @entity3146 ) grades I-III, @entity957 ( @entity957 ) and @entity420 ( @entity420 ) cases, respectively. Most @entity957 cases (81.3%) had only one HPV genotype detected and almost a third (32.0%) of all cervical pathologies were HPV negative including 51.9% of @entity3146 I (n   =   283), 34.1% @entity3146 (n   =   145), 18.7% of @entity3146 (n   =   146), 7.8% of @entity957 (n   =   5) and 35.7% of @entity420 (n   =   5) cases. CONCLUSIONS: This study provides important baseline data for monitoring the effect of HPV vaccination in NI and for comparison with other UK regions. The coverage of other HR-HPV genotypes apart from 16 and 18, including HPV-45, 31, 39 and 52, and the potential for cross protection, should be considered when considering future polyvalent vaccines. This article is protected by copyright. All rights reserved.

title: HPV prevalence and type-distribution in cervical XXXX and premalignant lesions of the cervix: A population-based study from Northern Ireland.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cervical cancers']

entities_list: @entity1083 :: ('MESH:D030361', 'Disease') :: ['HPV infection']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['SCC', 'squamous cell carcinomas']

entities_list: @entity1082 :: ('10566', 'Species') :: ['Human papillomavirus (HPV']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['AC', 'adenocarcinoma']

entities_list: @entity3146 :: ('MESH:D018290', 'Disease') :: ['CIN II', 'cervical intraepithelial neoplasias', 'CIN', 'CIN III']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: BACKGROUND: @entity284 maintenance treatment (MMT) reduces the harms of @entity4784 and is being rapidly scaled-up in China. This study evaluated the real-world implementation of MMT system in Wuhan, China. METHODS: Data extracted from electronic medical records collected in 2010 on 8811 @entity1 were used to compute for each @entity1 indices of the prescribed and consumed daily @entity284 doses, an adherence index, dose adjustments following missed doses, the rates of opiate positive urine tests, self-reported drug use, @entity734 ( @entity734 ), and the duration of MMT exposure. FINDINGS: The modal daily doses prescribed were 60mg and above for 68.5% of @entity1 . Adherence was variable: 51% of @entity1 attended less than 60% and 26% attended 80-100% of their treatment days; and @entity1 with long MMT exposure had significantly higher adherence rates than @entity1 with short MMT exposure. The differences between doses dispensed immediately before and after the interruption in dosing days ranged from 0 to 7mg, independently of the length of the interruption or the prescribed dosing level. The overall rate of opiate positive tests was 20%; 45% of @entity1 had at least one opiate positive test; 29% reported past month drug use and 53% of them reported past month @entity734 . Adherence and MMT exposure duration correlated significantly with the proportion of opiate negative urine tests (r=0.355, p<0.001; r=0.351, p<0.001, respectively). Treatment for males and females was comparable. CONCLUSIONS: Provision of safe @entity284 dosing after absences and improving daily attendance are identified as priority improvement areas.

title: Evaluation of an implementation of XXXX maintenance treatment in China.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity4784 :: ('MESH:D009293', 'Disease') :: ['opioid use disorder']

entities_list: @entity734 :: ('MESH:D019966', 'Disease') :: ['IDU', 'injection drug use']

entities_list: @entity284 :: ('MESH:D008691', 'Chemical') :: ['Methadone', 'methadone']

answer: @entity284 :: (MESH:D008691,Chemical) :: ['methadone']


abstract: BACKGROUND: @entity715 are a group of prevalent and life-threatening diseases. Selective inhibition of pathological @entity715 holds the key to treat variety of @entity715 . The pathological @entity715 can be induced by either tissue @entity39 and deregulated @entity32 . @entity518 , as an important proinflammatory cytokine and a late mediator, also involves on @entity715 disease. However, the underlying mechanisms are not fully understood. METHODS: Immunofluorescence, ELISA assay, Platelet Aggregation, Thromboelastogram (TEG) analyzes. Flow cytometric analysis and Western blot analysis were used to investigated the role of @entity518 in @entity1423 and obtained following observations. RESULTS: By doing so, we obtained the following observations: i) Highly purified @entity518 recombinant protein induces @entity1423 and secretion in a dose-dependent manner in the presence of serum. ii) Low concentration of extracellular @entity518 could synergistically promote subthreshold concentration of collagen or @entity556 induced @entity1423 . iii) Extracellular @entity518 promoted @entity1423 in a platelet-expressed @entity1427 /IIIa-dependent manner. iv) We proposed that extracellular @entity518 seems to promote the phosphorylation of @entity1427 /IIIa and subsequent @entity1423 via @entity2939 /NF-kB and @entity6708 pathway. CONCLUSIONS: In this study, we provide evidence for the hypothesis that @entity518 interact with platelet might play an important role in the haemostasis and @entity715 . Our research might be provide an interesting avenue for the treatment of @entity715 in the future.

title: XXXX : a novel protein that induced platelets active and aggregation via @entity2939 , NF-kB and @entity6708 dependent mechanisms.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity1423 :: ('MESH:D001791', 'Disease') :: ['platelet aggregation']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['Thrombotic diseases', 'thrombotic diseases', 'thrombosis']

answer: @entity518 :: (3146,Gene) :: ['HMGB1']


abstract: CONTEXT: @entity5445 ( @entity5445 ) and @entity8142 agonist treatment in type 2 @entity6 (T2DM) reduce blood @entity413 and food intake. It has been suggested that these effects are partly mediated through central @entity5445 receptors (GLP-1Rs). The rodent and nonhuman primate hypothalamus show clear @entity8142 expression. However, a detailed description of @entity8142 expression in the @entity1 hypothalamus is lacking, and it is unknown whether this expression is altered in T2DM @entity1 . OBJECTIVE: The objective of the study was to investigate the @entity8142 distribution in the @entity1 postmortem hypothalamus and to determine whether hypothalamic @entity8142 expression is altered in T2DM @entity1 . DESIGN: We investigated the distribution of @entity8142 expression throughout the @entity1 hypothalamus by means of in situ hybridization. We also performed quantifications of @entity8142 mRNA expression in two hypothalamic nuclei (ie, the paraventricular nucleus [PVN] and infundibular nucleus [IFN]), comparing @entity1 with T2DM and control subjects. RESULTS: We found that @entity8142 mRNA was expressed in a number of hypothalamic nuclei including the PVN and the IFN, both involved in the regulation of energy metabolism. We observed sporadic colocalization of the @entity8142 in the IFN with the orgexigenic neuropeptide Y, agouti-related peptide, or proopiomelanocortin transcripts. Comparison of @entity8142 mRNA in the PVN and IFN between T2DM @entity1 and control subjects revealed a decreased expression in T2DM @entity1 . CONCLUSIONS: Our studies show that @entity8142 is widely expressed throughout the @entity1 hypothalamus. The decreased expression of @entity8142 in the PVN and IFN of T2DM @entity1 may be related to the dysregulation of feeding behavior and @entity413 homeostasis in T2DM.

title: Decreased Hypothalamic @entity5445 Receptor Expression in Type 2 XXXX @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity5445 :: ('2641', 'Gene') :: ['Glucagon-like peptide-1', 'GLP-1']

answer: @entity6 :: (MESH:D003920,Disease) :: ['Diabetes']


abstract: In the last 18 years we have followed 330 @entity1 with @entity66 ( @entity66 ), diagnosed according to the ESPGAN criteria (with 3 jejunal biopsies: during the acute phase, after a gluten-free diet and after a gluten challenge). One to fifteen years after the diagnosis, 61 of them asked to be exposed to a second gluten challenge to see if their intolerance was persistent. Ten percent of them had already started the challenge by themselves, the others were on @entity1593 ( @entity1593 ). To all 61 serial clinical controls, one-hour-blood- @entity6122 absorption test every three months and a jejunal biopsy was suggested. The jejunal biopsy was performed when symptoms recurred, or when xylose-test showed an impaired absorption, or after 2 years. If the first jejunal biopsy showed a villous atrophy the @entity1593 was restarted, while if a normal mucosa was found the gluten challenge was continued and the jejunal biopsy repeated every year. 52 @entity1 (85%) showed a villous atrophy after 1.5 to 72 months. 6 (10%) did not show a clinical or histological relapse, 2 refused the jejunal biopsy because symptomless, and 1 had to restart the @entity1593 because she developed a @entity14086 . One-hour-blood-xylose test was performed in 29 @entity1 and 20 (69%) showed a low absorbtion, the majority of them in the first year of challenge, and the remaining refused it. 36 of the relapsed @entity1 presented with mild clinical symptoms while 16 were symptomless.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Clinico-histological behavior of celiac XXXX after gluten load following the definitive diagnosis].

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity1593 :: ('MESH:D002446', 'Disease') :: ['GFD', 'Gluten Free Diet']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['Coeliac Disease', 'CD']

entities_list: @entity14086 :: ('MESH:D003874', 'Disease') :: ['dermatitis herpetiformis']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: To better characterize the changes in left ventricular ejection fraction after @entity583 , we compared radionuclide ventriculograms obtained acutely and 2 weeks after @entity583 in 40 @entity1 . These @entity1 underwent angiography within a mean of 4 hr and 20 min after the onset of symptoms of @entity1188 and either received no therapy (32 @entity1 who were control subjects in a thrombolysis trial) or did not experience reperfusion (eight @entity1 ) despite receiving streptokinase infusions. In all 40 @entity1 , the change in left ventricular ejection fraction over 2 weeks was small (+2.6%). @entity1 were then grouped according to the presence or absence of residual flow on their angiograms. Residual flow was considered to be present in 21 @entity1 , in 12 by virtue of subtotal occlusion of the artery supplying the area of @entity1188 and in nine because of well-developed coronary collaterals to the @entity1188 . Mean change in ejection fraction for @entity1 with residual flow was +6.9 +/- 2.3% vs -2.2 +/- 1.7% for @entity1 without residual flow (p less than .01). Fourteen of 21 (67%) @entity1 with residual flow had a spontaneous rise in ejection fraction of greater than 5%, as compared with two of 19 (11%) @entity1 without residual flow (p less than .01). Time to peak level of @entity908 kinase (CK) was significantly shorter in the residual flow group (15 vs 23 hr, p less than .01), while the peak level of CK was lower (1550 vs 2220 IU) in these @entity1 . This latter difference did not reach statistical significance (p = .10).(ABSTRACT TRUNCATED AT 250 WORDS)

title: Arteriographic predictors of spontaneous improvement in left ventricular function after XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'acute myocardial infarction']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['distal infarct artery', 'infarct', 'infarction']

entities_list: @entity908 :: ('MESH:D003401', 'Chemical') :: ['creatine']

answer: @entity583 :: (MESH:D009203,Disease) :: ['myocardial infarction']


abstract: In the therapy of primary @entity43 in which the @entity5 is located in one ovary, radical operation including the uterus and contralateral ovary is performed in principle even in the case of young @entity1 . However, there have been only a few results reported on the primary cases in our country, and the radical operation is adopted at present in line with western policy. In the present study, the authors examined mainly the prognosis of 49 @entity1 with primary @entity43 (stage Ia, 25 cases; stage Ib, 2 cases; stage Ic, 22 cases), and the following results were obtained. Among 25 cases at stage Ia, the radical operation was performed on 14 cases, and only the conservative operation was performed on the remaining 11 cases. All of the latter are still well. Only one died among @entity1 at stage Ia. Therefore, in these cases, complete treatments were done, including radical operation, postoperative irradiation and chemotherapy, and second look operation. The prognosis of the @entity1 at Ic was worse than that at IIa + b. Therefore, it was felt to be necessary to treat them as progressive @entity5 . There was no difference between the prognoses of the conservative and radical operations even at stage Ic. Thus, problems such as functional maintenance were thought to be taken into consideration. Risk factors considered were tissue type, amount of @entity843 , capsular rhexis, and advanced age, etc. Since the prognosis after the second look operation was good, it was considered to be a treatment which should be introduced actively, even at stage I.

title: [Assessment of cases with XXXX stage I].

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

answer: @entity43 :: (MESH:D010051,Disease) :: ['ovarian cancer']


abstract: PURPOSE: To investigate gray-scale and color Doppler sonographic (US) features of @entity1557 ( @entity1557 ), according to the Breast Imaging-Reporting and Data System (BI-RADS) lexicon. METHODS: From 2010 through 2013, 586 @entity1 with @entity24344 were seen; 101 (17%) of those lesions were diagnosed as complex @entity24344 on percutaneous needle biopsy or surgery. Among the @entity1 with complex @entity24344 , 67 who had US examination results available were included in this study. In addition, the results from 98 @entity1 who had simple @entity24344 were included as controls. US features were retrospectively analyzed by two breast radiologists in consensus for shape, margin, echogenicity, posterior acoustic pattern, boundary, orientation, and associated findings. They also reassessed the BI-RADS category for @entity24344 . Color Doppler US examination results were classified according to the amount of vascularity as absent, moderate, or marked. RESULTS: Complex @entity1557 were larger than simple @entity24344 were (14.5 cm versus 12.1 cm, p > 0.05). On univariate analysis, a round to irregular shape, an uncircumscribed margin, the presence of associated findings, and BI-RADS categorization as 4a and 4b were more frequently revealed in complex than in simple @entity24344 (p < 0.05). Multivariate analysis revealed that the @entity5 margin was a predictive factor for complex @entity1557 (odds ratio: 6.08; 95% confidence interval: 1.14-32.49, p < 0.05). On color Doppler US, the complex @entity24344 had higher degrees of vascularity than simple @entity1557 (p < 0.05). CONCLUSIONS: Complex @entity24344 , in comparison with simple @entity24344 , tend to have more aggressive features and to be in higher BI-RADS categories on US examination.

title: Gray-scale and color Doppler sonographic features of complex XXXX of the breast.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity1557 :: ('MESH:D018226', 'Disease') :: ['FA', 'complex fibroadenoma']

answer: @entity1557 :: (MESH:D018226,Disease) :: ['fibroadenomas']


abstract: In a randomized, double-blind, placebo-controlled trial, 331 @entity1 aged 6 to 12 months received orally, at an interval of 1 month, either two doses of live attenuated @entity291 rotavirus vaccine strain RIT 4237 or equivalent placebo. The vaccinations were carried out during September to November, a non-rotavirus season; only three cases of rotavirus @entity294 occurred in the study group before the vaccinations were completed. During the @entity3082 season from December to May, 31 @entity1 with clinically significant rotavirus @entity294 required therapy. Five of these were among the 168 vaccine recipients, and 26 among the 160 placebo recipients (P less than 0.001), giving a vaccine protection rate of 82%. The incidence of clinically significant @entity294 from all causes was reduced by 76% in the vaccinees. As determined by an enzyme immunoassay antibody test with homologous virus antigen, seroconversion after vaccination was obtained in 53% of the initially seronegative @entity1 . Clinical protection correlated well with seroconversion, but the vaccinees who failed to seroconvert also had less rotavirus @entity294 than the placebo recipients, suggesting that immunity may be mediated by factors other than serum EIA antibody. Seventeen of the 23 rotavirus isolates in the @entity3082 season that were typed were of serotype 1, two were of serotype 2, and four were of serotype 3. The protection rates against clinically significant @entity294 were 72%, 100%, and 100% for serotypes 1, 2, and 3, respectively. We conclude that @entity18330 associated with @entity1 rotaviruses can be significantly reduced by vaccination with the live attenuated RIT 4237 @entity291 rotavirus vaccine before the @entity3082 season.

title: Clinical efficacy of the RIT 4237 live attenuated @entity291 rotavirus vaccine in @entity1 vaccinated before a rotavirus XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients', 'infants']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity18330 :: ('MESH:D003968', 'Disease') :: ['epidemic infantile winter diarrhea']

answer: @entity3082 :: (MESH:D004671,Disease) :: ['epidemic']


abstract: Aim/Background: A 1-bp deletion ( @entity45306 ) in the @entity11373 (also known as arrestin or @entity11373 ) gene is the most frequently seen mutation in Japanese @entity1 suffering from @entity39489 , a @entity74 . We investigated macular function in a @entity1 with @entity39489 with the @entity45306 mutation. Methods: A 43-year-old Japanese male @entity1 was diagnosed with @entity39489 . The @entity1 underwent complete ophthalmic examinations, including spectral-domain optical coherence tomography and Humphrey visual field testing. Full-field electroretinograms (ff-ERG) and multifocal ERG (mf-ERG) were recorded. Mutational analysis of the @entity11373 gene was performed. Results: Corrected visual acuity was @entity735 . Funduscopy showed retinal pigment epithelium @entity194 along the vascular arcade bilaterally. The inner segment-outer segment (ISOS) boundary lines were preserved in the foveal and parafoveal areas, whereas ISOS boundary defects and thinning of the outer nuclear layer (ONL) were seen outside the preserved ISOS boundary. Humphrey testing showed significant paracentral field @entity735 . In addition to an absence of rod responses, cone and 30-Hz flicker responses were markedly reduced in ff-ERG. The central ( @entity16720 ) and paracentral ( @entity21415 ) responses with normal latencies were relatively preserved, but the outer waveforms (rings 3-5) were attenuated and prolonged in mf-ERG. The deletion mutation ( @entity45306 ) was identified homozygously. Conclusions: The reduced/delayed mf-ERG responses and @entity227 in paracentral macula areas are most likely to be correlated with ISOS boundary defects and thinning of the ONL. @entity409 can occur in @entity39489 with the @entity45306 mutation in the @entity11373 gene.

title: Macular Dysfunction in @entity39489 with the Frequent Mutation XXXX in the @entity11373 Gene.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual field defects']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['Macular dysfunction']

entities_list: @entity735 :: ('MESH:D005124', 'Disease') :: ['good in both eyes', 'defects in both eyes']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['recessively inherited stationary night blindness']

entities_list: @entity39489 :: ('MESH:C537743', 'Disease') :: ['Oguchi disease']

answer: @entity45306 :: (c|DEL|1147|A,DNAMutation) :: ['1147delA']


abstract: A clinical trial is currently under way to examine the effectiveness of @entity3086 as a @entity0 chemopreventive agent and contraceptive. This trial, as well as similar proposed studies, is based on the assumption that @entity3086 is as effective as surgical castration in preventing the onset of @entity5 ; however, this has not been well documented in the @entity106 animal model. We directly compared @entity3086 and oophorectomy in this model and examined a combined therapy of @entity3086 / @entity2847 . Twenty-seven day old female @entity35 were randomly allocated into one of eight groups. All @entity35 received a 20-mg dose of @entity106 at the age of 55 days. Group 1 (n = 10), no treatment; Group 2 (n = 9), @entity3086 (100 microg/kg/day) for eight weeks beginning four weeks prior to @entity106 ; Group 3 (n = 10), oophorectomy four weeks prior to @entity106 with replacement @entity172 beginning four weeks following @entity106 . @entity172 replacement was achieved with a 0.05-mg @entity53 tablet releasing 0.833 microg/day over a 60-day period. Group 4 (n = 10), @entity3086 (100 microg/kg/day) initiated two weeks prior to @entity106 and continuing for two weeks following @entity106 ; Group 5 (n = 9), oophorectomy two weeks prior to @entity106 with 0.05 mg of @entity53 in depot form, releasing 0.833 microg/day, beginning four weeks following @entity106 and continuing until week 16 of the study; Group 6 (n = 10), @entity3086 (100 microg/kg/day) beginning two weeks prior to @entity106 and continuing for the duration of the experiment; Group 7 (n = 10), @entity3086 (100 microg/kg/day) for eight weeks beginning two weeks prior to @entity106 ; Group 8 (n = 9), @entity3086 (100 microg/kg/day) and @entity2847 (83 microg/day) for eight weeks beginning two weeks prior to @entity106 . At nineteen weeks (15 weeks post @entity106 ), animals were sacrificed and autopsies performed. One hundred percent of untreated animals developed @entity5 . No animals undergoing oophorectomy four weeks prior to @entity106 or receiving @entity3086 four weeks prior to and simultaneously with @entity106 developed @entity5 . In animals pretreated two weeks prior to @entity106 with @entity3086 or oophorectomy, each group had one animal with @entity5 development. No @entity5 developed in the animals receiving ongoing injections of @entity3086 . However, one @entity5 developed in those receiving @entity3086 for the first eight weeks beginning two weeks prior to @entity106 administration. One animal receiving both @entity3086 and @entity2847 developed one @entity5 . We conclude that chemical oophorectomy (with @entity3086 ) is as effective as surgical oophorectomy in inhibiting @entity106 induced @entity105 .

title: Prevention of XXXX mammary carcinoma utilizing @entity3086 as an equivalent to oophorectomy.

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen', 'Estrogen']

entities_list: @entity3086 :: ('MESH:D016729', 'Chemical') :: ['leuprolide']

entities_list: @entity2847 :: ('MESH:D001971', 'Chemical') :: ['bromocriptine']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'mammary tumors', 'tumors']

entities_list: @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol']

entities_list: @entity35 :: ('10116', 'Species') :: ['Sprague-Dawley rats', 'rats']

entities_list: @entity105 :: ('MESH:D063646', 'Disease') :: ['carcinogenesis']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: The development of new procedures and protocols that allow researchers to obtain recombinant proteins is of fundamental importance in the biotechnology field. A strategy was explored to overcome inclusion-body formation observed when expressing an aggregation-prone fungal xylanase in @entity526 . pHsh is an expression plasmid that uses a synthetic @entity1457 ( @entity1457 ) promoter, in which gene expression is regulated by an alternative sigma factor (  (32)). A derivative of pHsh was constructed by fusing a signal peptide to xynA2 gene to facilitate export of the recombinant protein to the periplasm. The xylanase was produced in a soluble form. Three factors were essential to achieving such soluble expression of the xylanase: 1) the target gene was under the control of the @entity1457 promoter, 2) the gene product was exported into the periplasm, and 3) gene expression was induced by a temperature upshift. For the first time we report the expression of periplasmic proteins under the control of an @entity1457 promoter regulated by   (32). One unique feature of this approach was that over 200 copies of the @entity1457 promoter in an @entity526 cell significantly increased the concentration of   (32). The growth inhibition of the recombinant cells corresponded to an increase in the levels of soluble periplasmic protein. Therefore, an alternative protocol was designed to induce gene expression from pHsh-ex to obtain high levels of active soluble enzymes.

title: An approach to the production of soluble protein from a fungal gene encoding an aggregation-prone xylanase in XXXX .

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli', 'E. coli']

answer: @entity526 :: (562,Species) :: ['Escherichia coli']


abstract: An open study was undertaken to investigate the efficacy and adverse effects of @entity7689 in 33 @entity1 with essential @entity101 whose blood pressure was uncontrolled (diastolic blood pressure 96 to 115 mm Hg) despite previous treatment with one or two antihypertensive drugs. @entity7689 was added to the existing antihypertensive therapy and the dose titrated to a maximum of 150 mg/day or until blood pressure control was achieved (diastolic blood pressure less than 90 mm Hg or a reduction in diastolic blood pressure of 15 mm Hg). @entity1 were then followed up for a further 4 weeks. @entity7689 significantly reduced mean standing systolic and diastolic blood pressure from 167/113 +/- 19.8/7.2 (SD) mm Hg to 150.3/101.1 +/- 23.4/8.9 (SD) mm Hg after 10 weeks and mean supine systolic and diastolic blood pressure from 169.8/110.8 +/- 16.4/5.6 (SD) mm Hg to 154.2/102.1 +/- 23.8/12 (SD) mm Hg after 10 weeks. Blood pressure was controlled in 21 of the 33 @entity1 (63.6%) studied. @entity7689 caused a small but significant fall in pulse rate of 3.9 beats per minute, in the supine position, after 4 weeks therapy. 10 @entity1 experienced adverse effects, the most common being dizziness and @entity10 (3 @entity1 each), and lightheadedness/fainting on standing (2 @entity1 ). No @entity1 experienced sedation. Only 1 @entity1 was withdrawn from the trial because of adverse effects (fainting on standing). Biochemical and haematological investigations carried out pretreatment and during treatment showed no abnormalities related to @entity7689 treatment.

title: [Open study on the effect and side effects of XXXX , used at the 2d and 3d therapeutic step in essential @entity101 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

entities_list: @entity7689 :: ('MESH:D007217', 'Chemical') :: ['indoramin', 'Indoramin']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

answer: @entity7689 :: (MESH:D007217,Chemical) :: ['indoramin']


abstract: The effect of circulatory arrest of the @entity291 and foot and head-up tilt upon pressure gradient over the thigh and distribution of muscle blood flow in the thigh was studied in 14 @entity1 with occlusion of the superficial femoral artery. In the supine position circulatory arrest just below the knee initially reduced the directly measured mean arterial pressure gradient over the thigh by about 30% indicating that a similar proportion of total leg blood flow supplied the @entity291 and foot. Local muscle blood flow was measured by the local 133Xe washout technique proximally and distally in the thigh muscle. Total leg blood flow was measured by an indicator dilution technique. During 10 min of circulatory arrest of the @entity291 and foot local muscle blood flow in the thigh increased by approximately 35% proximally and distally. Total leg blood flow remained unchanged and the pressure gradient was reduced by about 10% as compared with that before tourniquet. During head-up tilt local muscle blood flow in the thigh decreased by about 30% proximally and distally. Total leg blood flow also decreased by about 30%. Circulatory arrest below the knee did not alter this response. These findings indicate that blood flow change uniformly in the thigh during head-up tilt and during tourniquet on the @entity291 . Furthermore blood flow to the @entity291 appears only to account for 30% of the arterial pressure drop over the collateral arteries in the thigh, indicating that thigh blood flow is of major importance for the pressure gradient over the collateral arteries.

title: Influence of thigh blood flow upon the arterial pressure gradient over the collateral arteries in XXXX with occlusion of the superficial femoral artery.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: @entity1014 phosphorylase (TP) is an enzyme that converts 5'-DFUR to @entity1487 and also acts as an angiogenic factor. Measurement of serum TP levels has recently become possible by highly sensitive enzyme-linked immunosorbent assay (ELISA). We examined 38 @entity1 with @entity356 to measure serum TP levels by highly sensitive ELISA method and tissue TP levels by conventional ELISA. In addition, immunohistochemical staining of normal and @entity5 tissues was also performed. Serum TP levels in @entity1 with stages III and IV and inoperable or recurrent @entity5 were significantly higher than those in healthy controls. A high correlation was found between serum TP levels and @entity5 TP levels (r=0.65, p<0.0001). Moreover, serum TP levels were about 1/2500 of @entity5 TP levels. Tissue TP values in @entity5 were significantly higher than those in normal tissue. On the other hand, no significant differences among the @entity5 stages were found in either serum or @entity5 tissue. In conclusion, we demonstrate that serum TP levels strongly reflect @entity5 TP levels, and it may predict clinicopathological factors, prognosis, or sensitivity of anti- @entity5 drugs.

title: Measurement of serum XXXX phosphorylase levels by highly sensitive enzyme-linked immunosorbent assay in @entity356 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity1014 :: ('MESH:D013936', 'Chemical') :: ['Thymidine']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric adenocarcinoma']

answer: @entity1014 :: (MESH:D013936,Chemical) :: ['thymidine']


abstract: INTRODUCTION: Peroral endoscopic myotomy (POEM) is an emerging treatment for @entity1318 . @entity86 has been found in a significant number of @entity1 , but it is unknown whether subjective reports of reflux correlate with objective pH testing. The purpose of this study was to compare the objective rate of reflux with standardized reflux symptom scales after POEM. Our hypothesis was that subjective symptoms would not correlate with objective measurement of reflux. METHODS AND PROCEDURES: Data on all @entity1 undergoing POEM were collected prospectively between August 2012 and June 2014 and included demographics, objective testing (48-h pH probe, manometry, endoscopy), as well as @entity354 ( @entity354 ), GERD symptom scale (GERSS), and antacid use. RESULTS: Forty-three @entity1 underwent POEM during the study period. The mean age was 53.5      17.4  years with a BMI of 29.6      8.4  kg/m(2), and 27 (63%) were male. Forty-two @entity1 (98%) completed at least 6  months of follow-up, and 26 (60%) underwent repeat pH measurement. @entity1282 scores improved from 4 (0-5) at baseline to 0 (0-3) (p  <  0.001). On follow-up pH testing, 11 (42%) were normal and 15 (58%) had elevated DeMeester scores. Postoperative GERSS or @entity354 scores did not correlate with DeMeester scores on Spearman's rank-order tests (r  =  0.02, p  =  0.93 and r  =  0.04, p  =  0.50, respectively). Postoperative PPI use was not significantly associated with normal or abnormal pH testing: 5 of 7 (71%) @entity1 who were taking PPIs postoperatively had abnormal DeMeester scores compared to 9 of 18 (50%) of @entity1 who were not taking PPIs (p  =  0.332). CONCLUSIONS: Peroral endoscopic myotomy provides excellent @entity1282 relief for @entity1 with @entity1318 , but is associated with a high rate of reflux on pH testing postoperatively. Subjective symptoms are not a reliable indicator of postoperative reflux. Routine pH testing should be considered in all @entity1 following POEM.

title: XXXX do not correlate with objective pH testing after peroral endoscopic myotomy.

entities_list: @entity1318 :: ('MESH:D004931', 'Disease') :: ['achalasia', 'esophageal achalasia']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['Postoperative reflux']

entities_list: @entity354 :: ('MESH:D005764', 'Disease') :: ['gastroesophageal reflux disease health-related quality of life', 'GERD-HRQL']

entities_list: @entity1282 :: ('MESH:D003680', 'Disease') :: ['Dysphagia', 'dysphagia']

answer: @entity354 :: (MESH:D005764,Disease) :: ['Gastroesophageal reflux symptoms']


abstract: Psoriatic epidermis has a rapid rate of turnover and produces a stratum corneum with an abnormal tonofilament composition. One polypeptide chain, (Mr 70,000) is absent or greatly decreased in relative amount and two other chains, (Mr 63,000 and 55,000), which are normally modified in the living cells, persists into the stratum corneum. Increasing the turnover of normal epidermis has been shown to cause the persistence of 63 and 55 kilodalton chains in the stratum corneum but does not affect the relative amount of 70 kilodalton chain. It has, therefore, been suggested that, in @entity1569 , the deficiency of the 70 kilodalton chain may occur prior to or simultaneously with the induction of increased tissue turnover. In the present study, the polypeptide chain composition of living @entity5144 has been examined. It is shown that the relative amounts of 70 kilodalton chain in psoriatic stratum corneum and involved living epidermis from the same site are not significantly different. The abnormality is, therefore, already present in the living cells and it appears that, in @entity1569 , the synthesis of the 70 kilodalton chain is defective. The uninvolved epidermis of psoriatics is intermediate between normal and involved @entity5144 both in the ability to synthesise the 70 kilodalton chain and to modify the 63 and 55 kilodalton chains. Comparisons of @entity535 compositions of proteins containing different proportions of 70 kilodalton chain suggest that it has a considerably higher content of @entity2228 and @entity563 than the other tonofilament chains. These studies suggest that the 70 kilodalton chain may be functionally different from the other tonofilament chains. The defect in its synthesis in @entity1569 is a relatively early event and may be involved with the induction of increased tissue turnover or induced by the same abnormal conditions as the increased tissue turnover.

title: The proteins of living XXXX .

entities_list: @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis']

entities_list: @entity2228 :: ('CHEBI:57305', 'Chemical') :: ['glycine']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

entities_list: @entity5144 :: ('MESH:D015535', 'Disease') :: ['psoriatic epidermis']

entities_list: @entity563 :: ('CHEBI:17822', 'Chemical') :: ['serine']

answer: @entity5144 :: (MESH:D015535,Disease) :: ['psoriatic epidermis']


abstract: INTRODUCTION: Dual supraorbital and occipital nerve stimulation (SONS and ONS) have shown promising efficacy in treating @entity10 . However, its functional outcome is not well studied. We report functional outcome of combined SONS and ONS for @entity2704 using verified metrics. METHODS: Consecutive @entity1 who have both supraorbital and occipital nerve stimulators and also underwent @entity2704 Disability Assessment (MIDAS) and Beck Depression Index (BDI) both pre- and postoperatively were studied. Outcome variables included net improvement of ranked MIDAS and BDI scores. Predictor variables included @entity1 with 50% improvement of @entity158 , disability status, number of years from diagnosis to implantation, and narcotic use. Multivariate analysis of variance (MANOVA) was performed to assess the correlation between the outcome and predictor variables. RESULTS: Sixteen @entity1 (12 female; age average 51.8 years) were studied. Follow-up ranged from 5 to 80 months (average 44.5    21.4 months). Eight had a positive response (50% improvement in @entity10 ) at most recent follow-up. Fifty percent improvement in @entity10 was the only predictor of outcome variables combined (total MIDAS, MIDAS-B, and BDI) (P = .021). Of note, this improvement in functional outcome was only significant during the perioperative period and not throughout the length of follow-up. No other predictive factors were significantly correlated with the functional outcomes. Among the predictor variables, a strong correlation was found for disability status being inversely related to reporting 50% improvement in @entity10 (r = -0.582). CONCLUSION: In @entity1 who had positive response to SONS and ONS, functional status as reflected by MIDAS and BDI had overall improvement in perioperative period. Unfortunately, this effect waned over the long-term follow-up.

title: 185   Long-term Follow-up in Functional Outcomes of Combined Supraorbital Nerve Stimulation and Occipital Nerve Stimulation for Chronic Headache XXXX .

entities_list: @entity2704 :: ('MESH:D008881', 'Disease') :: ['migraine', 'Migraine']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['primary headaches', 'headache']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: The aim of the present study was to evaluate the scope and the limitations of fine needle aspiration cytology (FNAC) in orbital and @entity3217 . This study was a retrospective audit of 389 cases of orbital and @entity3217 subjected to FNAC over a period of 12 years (1998-2009). The cyto-smears were reviewed and the lesions were categorized under different diagnostic categories in adult and pediatric population. Three hundred and one adult @entity1 (age >= 15 years) and 88 pediatric @entity1 (age  <=14 years) constituted the study group. In the adult population, there were 23.3% cases of @entity1071 and 12.6% of benign cysts. In the pediatric population, 18.2% cases had @entity1071 and 8% had benign cysts. Various @entity5 (9.6% in adults) included @entity5123 , @entity1653 , and @entity808 . @entity5 predominated in the pediatric population. A majority of @entity5 in adults were @entity5 (12.6%); @entity1893 being the most common followed by @entity189 (10.3%). Nearly 3.6% cases of soft tissue/ @entity79 and 6.3% of @entity3 were seen in adult population. However, most of the @entity5 in the pediatric population were malignant small blue round cell @entity5 (33%). FNAC is a cost-effective technique with good diagnostic value in the assessment of ophthalmic lesions, especially when sampling and interpretation are performed by experienced personnel in the light of clinico-radiological information.

title: Spectrum of orbital and XXXX : an analysis of 389 cases diagnosed by fine needle aspiration cytology.

entities_list: @entity808 :: ('MESH:D009442', 'Disease') :: ['schwannoma']

entities_list: @entity1071 :: ('MESH:D008232', 'Disease') :: ['infectious and lymphoproliferative lesions']

entities_list: @entity3217 :: ('MESH:D015821', 'Disease') :: ['ocular adnexal lesions']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['orbital tumors', 'Benign vascular tumors', 'lymphoreticular malignancies', 'malignant tumors', 'benign tumors', 'tumors']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['malignant epithelial tumors']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['bone sarcomas']

entities_list: @entity1653 :: ('MESH:D008579', 'Disease') :: ['meningioma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic tumors']

entities_list: @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma"]

entities_list: @entity5123 :: ('MESH:D008949', 'Disease') :: ['pleomorphic adenoma']

answer: @entity3217 :: (MESH:D015821,Disease) :: ['ocular adnexal lesions']


abstract: @entity70669 is a rare disorder characterised by a combination of anatomic anomalies, and @entity1032 due to a monosomy or trisomy 6q. So far only 12 suspected cases of monosomies 6q have been reported. @entity393 does not seem to be characteristic for this syndrome. We present the case of a @entity1 with @entity70670 . A bilateral severe @entity393 was confirmed by subjective and objective audiometry at the age of 12 years. The @entity1 was successfully equipped with hearing aids. Other features of the syndrome, i.e. @entity1032 , @entity4242 , asymmetric face, broad nasal bridge, @entity5766 , epicanthus, strabism, @entity6127 , @entity1757 and @entity410 were seen. Additionally, a tetraplegy and diaphragmal @entity547 had been diagnosed. The @entity1 was equipped with a @entity5274 because of @entity17304 . In the literature, the possibility of @entity2167 in monosomy 6q is rarely mentioned, although limited verbal speech skills have been reported. A syndromic character of @entity2167 in @entity70669 cannot be excluded. We advise detailed and early audiological testing of @entity1 with monosomy 6q.

title: Severe @entity393 in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['girl', 'children']

entities_list: @entity1032 :: ('MESH:D008607', 'Disease') :: ['mental retardation', 'mental and motor retardation']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures']

entities_list: @entity2167 :: ('MESH:D006311', 'Disease') :: ['hearing disorders']

entities_list: @entity1757 :: ('MESH:D006345', 'Disease') :: ['ventricular septum defect']

entities_list: @entity70670 :: ('MESH:C537807', 'Disease') :: ['partial monosomy 6q']

entities_list: @entity5274 :: ('MESH:D005184', 'Disease') :: ['gastrostomy tube']

entities_list: @entity17304 :: ('MESH:D009748', 'Disease') :: ['nutritional disorders']

entities_list: @entity4242 :: ('MESH:D008831', 'Disease') :: ['microcephaly']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['Hearing loss', 'sensory hearing loss']

entities_list: @entity6127 :: ('MESH:D007569', 'Disease') :: ['high arched palate']

entities_list: @entity5766 :: ('MESH:D006972', 'Disease') :: ['hypertelorism']

answer: @entity70669 :: (MESH:C537810,Disease) :: ['del(6q)-syndrome']


abstract: OBJECTIVE: Our research was conducted to analyze the outcomes of two laparoscopic splenectomy plus pericardial devascularization (LSPD) techniques in the management of portal @entity101 (PTH) and @entity6118 . METHODS: Between May 2012 and May 2013, 41 @entity1 with PTH and @entity6118 undergoing LSPD were retrospectively analyzed. Of them, 29 @entity1 received LSPD by LigaSure    Vessel Sealing System (LVSS) and Endo-GIA    universal endoscopic vascular linear staplers (Endo-GIA) (EG Group) and 12 @entity1 received LSPD by LVSS and Hem-o-Lock ( @entity1733 Group). Operating time, intraoperative @entity190 , postoperative course, and hospitalization costs were compared between the two LSPD combination techniques. RESULTS: There were no significant differences in preoperative @entity1 characteristics of the two groups. Significantly less operating time, intraoperative @entity86 were observed in EG Group. The incidence of @entity715 was lower in the EG Group (3.4 vs. 8.3  %), as well as the incidence of @entity3472 (0 vs. 8.3  %). @entity360 was not observed in either group. Uncontrolled bleeding warranted conversion to open surgery in one case in EG Group (conversion rate 3.4  %) and in two cases in @entity1733 Group (conversion rate 16.7  %). Two @entity1 (16.7  %) in @entity1733 Group underwent successful emergency exploratory laparotomy due to uncontrolled intraabdominal bleeding postoperatively. No re-operation was needed in EG Group. Two @entity1 experienced @entity1578 after surgery in each group. Of those, three @entity1 were managed successfully and one @entity1 refused further therapy. While the overall complication rate was significantly lower in EG Group (17.2 vs. 58.3  %, P  <  0.05), overall hospitalization costs remained significantly higher for EG Group. CONCLUSION: The results suggest that the modified Endo-GIA and LVSS technique is a safe and effective combination approach to LSPD with shorter operative time, less intraoperative @entity190 , lower conversion rate to laparotomy, shorter hospital stay, better recovery, and lower postoperative complication rate compared with the Hem-o-Lock and LVSS approach. Higher hospitalization expenses associated with the Endo-GIA and LVSS approach.

title: Comparison of two laparoscopic splenectomy plus pericardial devascularization techniques for management of portal @entity101 and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity1578 :: ('MESH:D017093', 'Disease') :: ['liver failure']

entities_list: @entity3472 :: ('MESH:D010185', 'Disease') :: ['pancreatic fistula']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['blood loss, and postoperative complications']

entities_list: @entity6118 :: ('MESH:D006971', 'Disease') :: ['hypersplenism']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['portal vein thrombosis']

entities_list: @entity360 :: ('MESH:D006471', 'Disease') :: ['Upper gastrointestinal hemorrhage']

answer: @entity6118 :: (MESH:D006971,Disease) :: ['hypersplenism']


abstract: STUDY DESIGN: Cross-sectional population-based study. OBJECTIVE: To study sex differences in consequences of @entity4512 ( @entity4512 ): limited functioning, work leave or disability, and healthcare use. SUMMARY OF BACKGROUND DATA: @entity4512 is a major public health problem in developed countries due to high prevalence rates and considerable consequences. There are indications that consequences of @entity4512 differ for @entity1 and @entity1 . METHODS: Data of a Dutch population-based study were used, limited to @entity1 25 to 64 years of age (n = 2517). Data were collected by a postal questionnaire. RESULTS: @entity1 with any @entity4512 report more healthcare use for @entity4512 , i.e., contact with a medical caregiver and use of medicines than @entity1 , while @entity1 report more @entity717 (ever in life) due to low back @entity158 only, irrespective of work status. None of the sex differences can be explained by age, household composition, educational level, smoking status, overweight, physical activity, and @entity158 catastrophizing. Older age was related to more limited functioning due to @entity4512 ( @entity1 ), @entity717 due to @entity4512 ( @entity1 ), and healthcare use due to @entity4512 ( @entity1 and @entity1 ). A one- @entity1 household was associated with @entity717 ( @entity1 ) and use of medicines ( @entity1 ). Low educational level was associated with limited functioning ( @entity1 ), work leave ( @entity1 ), contact with a medical caregiver ( @entity1 ), and @entity717 ( @entity1 and @entity1 ). Smoking was associated with limited functioning ( @entity1 ), work leave ( @entity1 ), and healthcare use ( @entity1 ). Physical inactivity was associated with limited functioning due to @entity4512 in @entity1 . @entity158 catastrophizing was associated with limited functioning, work leave, and healthcare use ( @entity1 and @entity1 ) and @entity717 ( @entity1 ). CONCLUSIONS: Consequences of @entity4512 show a slightly different pattern for @entity1 and @entity1 . @entity1 with any MPreport more healthcare use for @entity4512 , while @entity1 report more @entity717 due to low back @entity158 only. These sex differences can not be explained by general risk factors, but associations between these factors and consequences of @entity4512 show some sex differences.

title: Sex differences in consequences of XXXX .

entities_list: @entity4512 :: ('MESH:D059352', 'Disease') :: ['MP', 'musculoskeletal pain']

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Women', 'person', 'persons', 'men']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['work disability']

answer: @entity4512 :: (MESH:D059352,Disease) :: ['musculoskeletal pain']


abstract: Therapy for @entity978 ( @entity978 ) is associated with excellent long-term survival rates, of 80% of more. Extended follow up has described late treatment-related @entity137 , principally secondary @entity5 , @entity65 and @entity249 . Given the young age of many @entity1 , there is a desire to offer a more personalised approach, correlated to individual tumour biology that enables treatment de-escalation in low risk @entity1 to reduce @entity137 , and treatment intensification in high risk @entity1 to reduce treatment failure. Contemporary therapeutic strategies have involved risk assessment based on staging and clinical factors. The use of functional imaging with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) as a predictive tool to identify early non-responders has been well validated and outperforms the risk stratifying International Prognostic Score (IPS). @entity978 has particularly high FDG-avidity (97-100%), with FDG-PET scanning reflecting metabolic activity and acting as a surrogate biomarker for chemosensitivity. International consensus on the methods of reporting and interpreting FDG-PET scans has enabled their use to be standardised and reproducible. Given that primary therapy fails for 15-20% of @entity1 , the use of combined FDG-PET and computerised tomography (FDG-PET/CT) to provide a response-adapted strategy to guide management is under investigation in numerous prospective clinical trials. They aim to determine whether early response scanning can be used to directly modulate subsequent therapy, through intensifying or abbreviating chemotherapy regimens and/or omitting radiotherapy. Integrated multi-modality imaging and advanced conformal planning techniques have led to the emergence of radiotherapy strategies such as involved-node radiation (INRT) that aim to optimise treatment volumes and maintain efficacy whilst lowering @entity137 . Study groups have incorporated these modalities in trial designs to assess whether a PET-directed, individualised approach can become the new standard of care.

title: Risk- and response-adapted strategies for the management of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity249 :: ('MESH:D007246', 'Disease') :: ['infertility']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies']

entities_list: @entity978 :: ('MESH:D006689', 'Disease') :: ['HL', 'Hodgkin lymphoma']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']

answer: @entity978 :: (MESH:D006689,Disease) :: ['Hodgkin lymphoma']


abstract: PURPOSE: To examine the existence of novel protein products of the @entity1 lacrimal gland. METHODS: cDNA clones corresponding to a highly abundant @entity1 lacrimal gland mRNA were isolated and sequenced. Tissue distribution of expression was studied by Northern blot analysis, RNase protection analysis, and in situ hybridization. RESULTS: A highly abundant 600-base mRNA was identified, and corresponding cDNA clones were isolated. The mRNA has a 134-residue open reading frame encoding a secreted protein of 13458 Da. This protein shows 45.5% similarity to @entity1 salivary acidic @entity1521 -rich protein PRP 1 and has a similar domain structure, but, unlike other members of the @entity1521 -rich protein family, it lacks a conserved repetitive domain. The lacrimal @entity1521 -rich protein is encoded by a single gene, designated as @entity67373 . Expression of @entity67373 was also detected in the @entity1 submandibular, von Ebners, sublingual, and parotid glands. @entity67373 was expressed in the acinar cells of the lacrimal gland, and in the submandibular gland expression of the @entity67373 and PRP 1 genes was localized to the serous acini and demilunes. CONCLUSIONS: The @entity1 lacrimal gland produces a previously unknown member of the @entity1521 -rich protein family. By analogy with other @entity1521 -rich proteins, this @entity67373 most likely mediates protective functions in the eye, such as modulation of the microflora. In contrast to other @entity1521 -rich protein genes, @entity67373 is expressed in the lacrimal acinar cells, and other anterior exocrine glands. @entity67373 should be a useful marker for @entity1 lacrimal gland acinar cell function in vitro.

title: A major XXXX lacrimal gland mRNA encodes a new @entity1521 -rich protein family member.

entities_list: @entity1521 :: ('CHEBI:26271', 'Chemical') :: ['proline']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: Diagnosis-related groups (DRGs) have been mandated by the federal government to promote fiscal responsibility and insure cost containment. A retrospective analysis of demographic and cost data was conducted on 115 @entity1 operated on for @entity9007 . The DRG 191 criteria are as follows: major pancreas, liver plus shunt procedure; mean length of stay (LOS), 20.8 days; outlier cutoff LOS, 41 days; hospital reimbursement,  11,367.82; and day outlier rate,  86.57. The overall LOS was 34.6 days (range, one to 138 days). Sixty-six percent of the @entity1 exceeded the DRG LOS and 37% exceeded the day outlier cutoff of 41. The number of days from admission to surgery varied from one to 65 (mean, 15.7 days). Hospital charges and DRG reimbursement were compared in 23 @entity1 . In nine @entity1 with a LOS of 19.9 days, DRG reimbursement exceeded charges by  34,308. In 14 @entity1 whose charges exceeded reimbursement, the loss was  142,156. Hospital costs and LOS seem to be related to the natural history of the disease and its necessary treatment, rather than to unnecessary diagnostic procedures. Unless surgeons assess and establish medical standards, economic pressures will have a negative impact on @entity1 care and physicians' practice.

title: Do diagnosis-related groups accurately reflect the disease? XXXX : a case in point.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity9007 :: ('MESH:D010192', 'Disease') :: ['pancreatic pseudocyst']

answer: @entity9007 :: (MESH:D010192,Disease) :: ['Pancreatic pseudocyst']


abstract: OBJECTIVE: To study the effects of @entity21243 (UA) on the invasion and @entity3 of @entity43 cell HO-8910PM and its underlying mechanism. METHODS: @entity98 assay was performed to examine the effects of UA on the proliferation of @entity43 cells HO-8910PM in vitro. The effects of UA on the invasion and migration of HO-8910PM were evaluated using Transwell chambers attached with @entity6027 filters and reconstituted basement membrane. Gelatin zymography was performed to detect the activity of gelatinase in the HO-8910PM cells. The expressions of @entity1476 and @entity1495 in the HO-8910PM cells were measured by Western blot. RESULTS: UA inhibited the proliferation of HO-8910PM cells in a time- and dose-dependent manner. There was a statistically significant difference in the invasion and migration of HO-8910PM cells between the UA treated cells and the controls (P < 0.01, P < 0.05). UA inhibited the activity of gelatinase of the treated cells. CONCLUSION: UA downregulated the expressions of @entity1476 and @entity1495 . UA inhibits the invasion and @entity3 of HO-8910PM cells, probably through inhibiting the activity of gelatinase and the expressions of @entity1476 and @entity1495 .

title: [Inhibitive effect of XXXX on the invasion and @entity3 of @entity43 cells HO-8910PM].

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian carcinoma']

entities_list: @entity6027 :: ('CHEBI:61433', 'Chemical') :: ['polycarbonate']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity21243 :: ('MESH:C005466', 'Chemical') :: ['ursolic acid']

answer: @entity21243 :: (MESH:C005466,Chemical) :: ['ursolic acid']


abstract: OBJECTIVES: Some @entity1 with @entity6583 ( @entity6583 ) develop perilesional @entity5219 during the course of healing and carry poor prognosis for the @entity410 control. We evaluated the clinical status of these @entity1 during complete control of their original @entity410 on anti- @entity302 drugs (AED). MATERIAL AND METHODS: We studied 172 @entity1 with solitary @entity6583 , 45 with perilesional @entity5219 as visible on magnetization transfer spin echo (MTSE) magnetic resonance imaging and 127 without @entity5219 , for any abnormal symptom during the course of their " @entity410 -free" period. All of them received optimum doses of AED to control the original @entity410 . RESULTS: @entity1 with @entity5219 had high incidence of abnormal symptoms with or without corresponding abnormalities on surface electroencephalogram (EEG). These symptoms disappeared on increasing the dose or adding a new AED. The symptoms, which were transient episodic in nature, included heaviness, @entity3520 , weightlessness, @entity1183 and alien limb phenomenon on the side of the body contralateral to @entity75 , and @entity10 . CONCLUSION: @entity1 with @entity6583 who develop perilesional @entity5219 during the process of healing tend to suffer from disturbing intermittent symptoms during their apparent control of @entity410 . The symptoms are controllable with increased dosage of previously prescribed or addition of another AED. As these symptoms could possibly be @entity302 in nature, their identification and treatment may have a bearing on long-term @entity410 control after stopping AED therapy.

title: Intermittent symptoms in @entity6583 : could they be XXXX ?

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity6583 :: ('MESH:D020019', 'Disease') :: ['neurocysticercosis', 'NCC']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures']

entities_list: @entity3520 :: ('MESH:D020821', 'Disease') :: ['dystonic posturing']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['cerebral lesion']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epileptic']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

answer: @entity302 :: (MESH:D004827,Disease) :: ['epileptic']


abstract: The purpose of this work is to extract three-dimensional (3D) motion trajectories of internal implanted and external skin-attached markers from kV cone-beam projections and reduce image artifact from @entity1 motion in cone-beam computed tomography (CBCT) from on-board imager. Cone beam radiographic projections were acquired for a mobile phantom and liver @entity1 with internal implanted and external skin-attached markers. An algorithm was developed to automatically find the positions of the markers in the projections. It uses normalized cross-correlation between a template image of a metal seed marker and the projections to find the marker position. From these positions and time-tagged angular views, the marker 3D motion trajectory was obtained over a time interval of nearly one minute, which is the time required for scanning. This marker trajectory was used to remap the pixels of the projections to eliminate motion. Then, the motion-corrected projections were used to reconstruct CBCT. An algorithm was developed to extract 3D motion trajectories of internal and external markers from cone-beam projections using a kV monoscopic on-board imager. This algorithm was tested and validated using a mobile phantom and @entity1 with liver masses that had radio-markers implanted in the @entity5 and attached to the skin. The extracted motion trajectories were used to investigate motion correlation between internal and external markers in liver @entity1 . Image artifacts from respiratory motion were reduced in CBCT reconstructed from cone-beam projections that were preprocessed to remove motion shifts obtained from marker tracking. With this method, motion-related image artifacts such as blurring and @entity2167 were reduced, and contrast and position resolutions were improved significantly in CBCT reconstructed from motion-corrected projections. Furthermore, correlated internal and external marker 3D-motion tracks obtained from the kV projections might be useful for 4DCBCT, beam gating and @entity5 motion monitoring or tracking.

title: An algorithm to extract three-dimensional motion by marker tracking in the kV projections from an on-board imager: four-dimensional cone-beam CT and XXXX tracking implications.

entities_list: @entity2167 :: ('MESH:D006311', 'Disease') :: ['spatial distortion']

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumor']


abstract: UNASSIGNED: Since virtually no trials have evaluated the effectiveness of @entity2903 ( @entity2904 ) in the treatment of spinal cord (SC) @entity463 multiforme (GBM), we conducted a systematic review to evaluate its efficacy. Primary SC GBM is rare. Its management remains unclear, even though treatment guidelines have been established since 2005 for its cranial counterpart. We performed a medical subject heading search with the terms " @entity463 " and "primary @entity4097 , intramedullary". We stratified the papers into two groups according to the use of @entity2904 , and analyzed survival rates using the Kaplan-Meier method with a two-sided log-rank scale. The @entity2904 subgroup contained nine articles and a total of 19 @entity1 with primary SC GBM who were treated with adjuvant @entity2904 . The non- @entity2904 group consisted of 19 articles including 45 @entity1 who underwent other treatment modalities. The @entity2904 subgroup had an overall survival of 16months, compared to the non- @entity2904 group with a median overall survival of 10months. The difference between these two groups was not statistically significant (p=0.57). While this review did not demonstrate a statistically significant difference in long term survival between @entity1 with SC GBM treated with @entity2904 versus those not treated with @entity2904 , a slightly longer survival time was seen in the @entity2904 group. The small number of @entity1 is likely a contributing factor to the lack of statistical significance. Our analysis highlights the need for a multi-institutional, prospective, controlled study to evaluate the use of @entity2904 in the treatment of SC GBM.

title: Primary spinal cord glioblastoma multiforme treated with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity4097 :: ('MESH:D013120', 'Disease') :: ['spinal cord neoplasms']

entities_list: @entity2903 :: ('MESH:C047246', 'Chemical') :: ['temozolomide']

entities_list: @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma']

answer: @entity2903 :: (MESH:C047246,Chemical) :: ['temozolomide']


abstract: AIM: This study investigates the colonization rate of @entity30811 in the gastrointestinal tracts of @entity1 living in southern China and applies a modified method for the isolation and subtyping of A.  muciniphila strains from faecal samples. METHODS AND RESULTS: Fresh faecal samples were collected and bacterial DNA was extracted from these samples for real-time PCR analysis. Strains were separated using a culture-dependent sPCR-directed method and classified using an enterobacterial repetitive intergenic consensus (ERIC-PCR) DNA fingerprinting method. The colonization rate for the sample population from southern China was 51  74%. We isolated 22 strains from @entity1 faeces. The results revealed that all strains were identifiable as A.  muciniphila with 99-100% identity to the type-strain @entity30811 . ERIC-PCR resulted in grouping of the DNA fingerprints showed that 12 distinct clusters were distinguished with a delineation level of 100%. CONCLUSIONS: Southern China has a high rate of A.  muciniphila colonization and over 12 different subtype strains reside in faecal samples. SIGNIFICANCE AND IMPACT OF THE STUDY: @entity30811 has a beneficial role in @entity1 gastrointestinal tract. These studies provide a better understanding of A.  muciniphila and details of its colonization in the @entity1 gastrointestinal tract.

title: Different subtype strains of XXXX abundantly colonize in southern China.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'people']

entities_list: @entity30811 :: ('239935', 'Species') :: ['Akkermansia muciniphila', 'ATCC BAA-835']

answer: @entity30811 :: (239935,Species) :: ['Akkermansia muciniphila']


abstract: When a @entity1 fetal muscle cDNA library was screened with the @entity1 thyroid hormone receptor alpha 2 cDNA at low stringency, we found a weakly hybridizing cDNA. The sequence of the insert was 2498 basepairs, with an open reading frame of 1794 basepairs encoding a protein of 598 @entity1522 and a predicted molecular mass of 64 kDa. The DNA-binding domain and the ligand-binding domain are similar to those of @entity134 and thyroid hormone receptors. Moreover, this cDNA is highly homologous to @entity19 @entity39769 and @entity35 @entity27803 , which are early response genes induced by nerve growth factor and other serum growth factors. We designated this gene @entity5282 . The modulation of expression of @entity5282 during stimulation of cell growth was studied. The mRNA of @entity5282 was induced rapidly and transiently by growth-stimulating agents, such as @entity857 , in monkey kidney cells ( @entity35635 ), by phytohemagglutinin in @entity1 lymphocytes, and by serum stimulation of arrested fibroblasts. It is expressed in @entity1 fetal muscle and adult liver, brain, and thyroid. @entity5282 could be a nuclear receptor. It will be of great interest to determine the ligand for @entity5282 and the genes that are regulated by it.

title: A @entity1 early response gene homologous to XXXX @entity39769 and @entity35 @entity27803 , and related to the nuclear receptor superfamily.

entities_list: @entity1522 :: ('CHEBI:33709', 'Chemical') :: ['amino acids']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity857 :: ('MESH:D000244', 'Chemical') :: ['adenosine diphosphate']

answer: @entity19 :: (10090,Species) :: ['murine']


abstract: UNASSIGNED: PPAR gamma was a key nuclear receptor, playing an important role in the immune defense and the anti-inflammatory mechanism. In this study, the full-length PPAR gamma (EcPPAR gamma) was obtained, containing a 5'UTR of 133  bp, an ORF of 1602  bp and a 3'UTR of 26  bp besides the poly (A) tail. The EcPPAR gamma gene encoded a protein of 533 @entity1522 with an estimated molecular mass of 60.02  KDa and a predicted isoelectric point (pI) of 6.26. The deduced @entity535 sequence showed that EcPPAR gamma consisted of the conserved residues and the domains known to be critical for the PPAR gamma function. The quantitative real-time PCR analysis revealed that EcPPAR gamma transcript was expressed in all the examined tissue, while the strong expression was observed in intestine, followed by the expression in liver, gill, spleen heart, kidney and muscle. Vibrio challenge could stimulate the inflammatory response in grouper and induce a sharp increase of pro-inflammatory cytokines expression, lipid peroxidation and DNA damage, while the up-regulation of vibrio-induced @entity32 could also increase the non-specific immune defense. The groupers challenged with @entity12671 showed a sharp increase of EcPPAR gamma transcript in immune tissues. Subcellular localization analysis revealed that EcPPAR gamma was distributed in the nucleus. Furthermore, overexpression of EcPPAR gamma could down-regulated the expression of IL1b, IL6, TNF1 and TNF2. In addition, the administration of PPAR gamma antagonist, @entity4301 , could up-regulate the expression of pro-inflammatory genes, including IL1b, IL6, TNF1 and TNF2. Together, these results indicated that EcPPAR gamma serving as a negative regulator of pro-inflammatory cytokines may play an important role in the immune defense against vibrio-induced @entity32 in grouper.

title: Molecular cloning, characterization and expression analysis of PPAR gamma in the orange-spotted grouper (Epinephelus coioides) after the XXXX challenge.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity12671 :: ('663', 'Species') :: ['Vibrio alginolyticus']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

answer: @entity12671 :: (663,Species) :: ['Vibrio alginolyticus']


abstract: BACKGROUND: Few studies have examined the relationship between mircroRNAs and @entity7025 ( @entity7025 ). We performed a study of the significance of @entity10075 expression in the serum of @entity7025 @entity1 . METHODS: The experimental group includes 49 @entity7025 @entity1 , and the control group consists of 30 normal @entity1 , 20 @entity1779 @entity1 , 20 massive @entity385 @entity1 , 20 nonmassive @entity385 @entity1 , and 20 neurological @entity792 @entity1 . Let-7 family levels were determined by polymerase chain reaction. A dual luciferase assay was used to test whether @entity10075 recognized the 3'UTR of @entity8731 . RESULTS: The expression level of @entity10075 in @entity7025 @entity1 is higher than that observed in the control groups (P  <  .001). The luciferase assay results indicated that @entity10075 could diminish luciferase activity from a reporter vector containing the 3'-UTR of @entity8731 (P  <  .05). The suppression of luciferase activity is not found in mutRNF213 (P  >  .05). CONCLUSIONS: Increased expression of @entity10075 in @entity7025 @entity1 may contribute to @entity7025 pathogenesis by targeting @entity8731 . Thus, @entity10075 may be a potential biomarker for the diagnosis of @entity7025 .

title: Elevated Serum MicroRNA XXXX in Moyamoya Disease.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'people']

entities_list: @entity7025 :: ('MESH:D009072', 'Disease') :: ['moyamoya disease', 'MMD']

entities_list: @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune disease']

entities_list: @entity1779 :: ('MESH:D002543', 'Disease') :: ['cerebral hemorrhage']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['cerebral infarction']

answer: @entity10075 :: (406885,Gene) :: ['Let-7c']


abstract: BACKGROUND AND PURPOSE: @entity2704 is a risk factor for clinical @entity64 and for subclinical @entity62 and @entity1188 . These subclinical lesions are linked to small-vessel pathology. @entity1779 ( @entity1779 ) are another biomarker of @entity6249 but have not yet been studied in @entity2704 . METHODS: Identification of @entity1779 in 63 migraineurs (25 with aura/35 without aura/3 unknown aura status) and 359 controls (aged, 73-85 years) from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) magnetic resonance imaging study. We assessed the modifying role of @entity2704 in the co-occurrence of @entity1779 , @entity1188 , and white matter hyperintensity-load. RESULTS: Infratentorial microbleeds were more prevalent in @entity5330 @entity1 than controls (14% versus 4%). Prevalence of other @entity1779 , @entity1188 , and @entity62 did not differ between groups. Migraineurs with @entity1779 had more often @entity1188 than controls with @entity1779 (65% versus 43%). In comparison with controls with @entity1188 , migraineurs with @entity1188 had more commonly @entity1779 (55% versus 30%). CONCLUSIONS: @entity2704 , notably without aura, is associated with infratentorial @entity1779 at older age. @entity1779 and @entity1188 co-occur more often in @entity2704 than in controls. This supports the hypothesis of small-vessel involvement in @entity2704 pathophysiology.

title: Infratentorial Microbleeds: Another Sign of Microangiopathy in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity6249 :: ('MESH:D059345', 'Disease') :: ['small-vessel disease']

entities_list: @entity5330 :: ('MESH:D020326', 'Disease') :: ['migraine without aura']

entities_list: @entity2704 :: ('MESH:D008881', 'Disease') :: ['migraine', 'Migraine']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['infratentorial infarcts', 'infarcts']

entities_list: @entity62 :: ('MESH:D056784', 'Disease') :: ['white matter hyperintensities']

entities_list: @entity1779 :: ('MESH:D002543', 'Disease') :: ['Cerebral microbleeds', 'CMBs']

answer: @entity2704 :: (MESH:D008881,Disease) :: ['Migraine']